Overview of the Market:
Through Hormone replacement therapy (HRT), a patient receives hormones, either to supplement a lack of naturally occurring hormones or to replace them with other hormones. Most of the hormone replacement therapies takes place for conditions like Menopause in woman (Estrogen Therapy). The Global Hormone Replacement Therapy Market is estimated at USD 15.75 billion in 2018 and is predicted to reach USD 22.31 billion by 2023, growing at a CAGR of 7.21%.
Nearly 80% of menopausal women experience mild symptoms. While a quarter have severe symptoms, of these only a small proportion of menopausal women currently take hormone replacement therapy. At present, combination of drugs is used to treat these conditions, which are known to have a better efficacy and safety parameter.
Increasing awareness on post-menopausal hazards, novel formulations, rise in unmet medical needs which require the employment of hormone therapy are the few factors driving the growth of global hormone replacement therapy market.
However, presence of side effects, such as bleeding, bloating, breast tenderness or enlargement, headaches, mood changes, and nausea, risk of breast cancer, heart disease, and stroke is restraining the growth of the market. Along with this, high cost of therapy is acting as a major hurdle. An average estrogen replacement therapy will cost $ 10,000 per annum to a patient. This is limiting its reach to middle class consumers, especially those of developing nations. Further, several researches shows that women with high susceptibility to coronary diseases should not go for hormone replacement therapy thereby decreasing the size of target audience.
The global hormone replacement therapy market is segmented on the basis of hormone type into Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid replacement therapy and others. With a market share of more than 60%, the estrogen replacement therapy segment dominates the market. And on the basis of route of administration the market is classified as oral, parenteral, transdermal and other routes. The oral route of administration is regarded as one of the safest and most preferred routes of drug administration.
Geographical Analysis:
Further, on the basis of geography, the hormone replacement therapy market is analysed under regions namely, North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. Moreover, under each region, major countries market values are provided. North America dominated the market, where the majority of the contribution was from the USA. While, the market in the APAC region is expected to witness a rapid growth during the forecast period.
Key Market Players in this Market:
Some of the key players operating in the hormone replacement industry are Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories, Amgen, Merck & Co., Bayer, Eli Lily, Novo Nordisk, Wyeth, F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co. Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Hormone Type
5.1.1 Estrogen Replacement Therapy
5.1.2 Growth Hormone Replacement Therapy
5.1.3 Thyroid Replacement Therapy
5.1.4 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Transdermal
5.2.4 Others
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Abbott Laboratories
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis
9.3 Pfizer
9.4 Mylan Laboratories
9.5 Amgen
9.6 Merck & Co.
9.7 Bayer
9.8 Eli Lily & Company
9.9 Novo Nordisk
9.10 Wyeth
9.11 F. Hoffmann-La Roche
9.12 Hisamitsu Pharmaceutical Co. Inc.
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
